Drug
Obinutuzumab
Obinutuzumab: highest development phase Phase 3, developed by Roche, TG Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Roche, TG Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Obinutuzumab NCT06084936 | Phase 3 | Lymphoma |
| Obinutuzumab NCT02612311 | Phase 3 | Chronic Lymphocytic Leukemia |
| Obinutuzumab NCT06806033 | Phase 2 | Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma |
Latest
No recent events.
Follow Obinutuzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.